Top Tweets for #ev103
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. π Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! π‘ A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. π Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! π‘ A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. π Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! π‘ A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. π Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! π‘ A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq
5-Year survival outcomes in cisplatin-ineligible patients from #EV103. @DrRosenbergMSK @MSKCancerCenter joins @CaPsurvivorship @DanaFarber discuss the 5-year results from EV-103 Cohort A in advanced urothelial cancer. π Over 40% alive at 5 yrs (vs ~3% w/ chemo), showcasing potential curative effects of enfortumab vedotin + pembrolizumab! π‘ A game-changer for survival & care. #FullVideo on UroToday > https://t.co/CINcu4pkrq
#EV103 study update: impressive 4-year data on enfortumab vedotin and pembro combination in #UrothelialCancer. @shilpaonc @CleClinicMD joins @CaPsurvivorship @DanaFarber and underscores the importance of diligent patient observation and dose adjustment > https://t.co/aklSiT9tkt
#EV103 study update: impressive 4-year data on enfortumab vedotin and pembro combination in #UrothelialCancer. @shilpaonc @CleClinicMD joins @CaPsurvivorship @DanaFarber and underscores the importance of diligent patient observation and dose adjustment > https://t.co/aklSiT9tkt
π«πLong-term data from #EV103 shows #enfortumabvedotin + #pembrolizumab as a promising chemotherapy-free option for metastatic urothelial carcinoma patients ineligible for cisplatin.
π ORR 73.3%
π DCR 84.4%
@shilpaonc @OncoAlert
@OncoReporte @OncLive @urotoday
#ASCO2023 #UrothelialCancer https://t.co/vgNSiUJARf
#EV103 study update: impressive 4-year data on enfortumab vedotin and pembro combination in #UrothelialCancer. @shilpaonc @CleClinicMD joins @CaPsurvivorship @DanaFarber and underscores the importance of diligent patient observation and dose adjustment > https://t.co/aklSiT9tkt
#BradleyCarthon @WinshipAtEmory with broad sweeping updates in #bladdercancer from neoadj, adj, and metastatic settings! Kudos to covering everything from #VESPER to Checkmate 274 to #JAVELINbladder to #EV103 cohort K results!!
#Pitt23 @UPMC @UPMCHillmanCC
Assessing the impact of enfortumab vedotin and pembrolizumab on QoL and symptom management in #UrothelialCarcinoma: #EV103 cohort K study results. @MattMilowsky @UNC_Lineberger joins @UroCancerMD @VUMCurology discuss patient-reported outcomes on UroToday > https://t.co/2mWVTMFQca
Assessing the impact of enfortumab vedotin and pembrolizumab on QoL and symptom management in #UrothelialCarcinoma: #EV103 cohort K study results. @MattMilowsky @UNC_Lineberger joins @UroCancerMD @VUMCurology discuss patient-reported outcomes on UroToday > https://t.co/2mWVTMFQca
Fantastic discussion re: 1L bladder cancer #IMVIGOR130 #NORSE #EV103, options and more work to be done @drenriquegrande Dr. Arlene Siefker-Radtke, @shilpaonc @BourlonMaite @NehaVapiwala @TiansterZhang #asco2023
Amazing presentation and discussion by @BourlonMaite at #blcsm oral session
Puting into context relevants trial #IMvigor130 by @grande
#NORSE by Dr. Siefker and #EV103 by @shilpaonc #ASCO23 @OncoAlert
The best #LATAM representative
Beautiful update from brilliant @shilpaonc of #EV103 cohort A results β 45 pts w met urothelial cancer txβd w EV-pembro, 73% ORR w 15% CR!!
41% of patients without progression at 2 years β this has not been seen for patients w #bladdercancer. @ASCO #Asco23 @OncoAlert
Phenomenal presentation by my friend, the brilliant @shilpaonc @ASCO #ASCO23
Results from #EV103: EV + pembro showing promising activity and tolerable safety profile in 1L cis ineligible #mUC
Beautiful tail for DOR and OS curves!
The one and only @shilpaonc rocks the stage with the impressive long-term results of #EV103
Median PFS: 12.7 months
Median DoR: 22 months #ASCO23
#EV103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with #MIBC: Updated results for Cohort H. Presented by @TomFlaigMD @CUAnschutz. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/GVYK9UD3Ub @ASCO
Top 5 #bladdercancer studies I'm eagerly awaiting this week @ASCO #ASCO23 --
#EV103 cohort A from @shilpaonc
#THOR from @y_loriot
#NORSE from #ArleneSiefkerRadtke
pembro/gem/XRT from @minaseconomides
@SWOG S1011 from @slernerbcmedu1
among many more...
@OncoAlert
Assessing the impact of enfortumab vedotin and pembrolizumab on QoL and symptom management in #UrothelialCarcinoma: #EV103 cohort K study results. @MattMilowsky @UNC_Lineberger joins @UroCancerMD @VUMCurology discuss patient-reported outcomes on UroToday > https://t.co/2mWVTMFQca
Last Seen Hashtags on Sotwe
bokepindo
Seen from Indonesia
Nature
Seen from United States
hotwifechallange
Seen from Germany
momson filter:videos
Seen from United States
ι²εΊ
Seen from Singapore
altertuguegarao
Seen from Philippines
sexoconhijo
Seen from Saudi Arabia
DAcademy8
Seen from United States
NhiccoXCreeper
Seen from Mexico
skandal ayah
Seen from Thailand
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.7M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.3M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.8M followers
Kim Kardashian
@kimkardashian
70.1M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers